Clin Mol Hepatol.
2024 Oct;30(4):1050-1052. 10.3350/cmh.2024.0546.
Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
- Affiliations
-
- 1Division of Gastroenterology and Hepatology, Stanford University Medical School, Stanford, CA, USA
- KMID: 2560126
- DOI: http://doi.org/10.3350/cmh.2024.0546
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
- Reply to correspondence on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”
- Anti-viral Treatment of Chronic Hepatitis B
- Hepatocellular Carcinoma Prediction Models for Patients with Chronic Hepatitis B Virus Infection in the Era of Potent Antiviral Therapy
- Quantitative hepatitis B surface antigen predicts the antiviral response and hepatocellular carcinoma development in patients with chronic hepatitis B
